Vicore Pharma Holding AB ( (SE:VICO) ) has shared an update.
At its annual general meeting, Vicore Pharma Holding AB approved several key resolutions, including the adoption of the 2024 financial statements, the re-election of board members, and the decision not to pay dividends for 2024. The company also authorized the issuance of new shares and implemented equity-based and long-term incentive programs for board members and senior management, respectively. These decisions aim to strengthen Vicore Pharma’s operational capabilities and align management incentives with shareholder interests, potentially impacting its strategic positioning in the pharmaceutical industry.
More about Vicore Pharma Holding AB
Vicore Pharma Holding AB is a clinical-stage pharmaceutical company focusing on developing innovative treatments for respiratory and fibrotic diseases, such as idiopathic pulmonary fibrosis (IPF). Their leading product, buloxibutid (C21), is an oral small molecule targeting the angiotensin II type 2 receptor, currently in a Phase 2b trial. The company is listed on the Nasdaq Stockholm exchange.
Average Trading Volume: 376,499
Current Market Cap: SEK1.98B
For a thorough assessment of VICO stock, go to TipRanks’ Stock Analysis page.